RxDoctor Payments Data

Ping Wang, MD

Family Medicine · Warren, MINPI 1407833627

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $74,620 of the $84,695 with a category attached, or 88.1%. Gilead accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $21,637 and has fallen 83.7% since, to $3,516 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$84,695in general payments, 2019–2025

Across 105 payments — averaging $806.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$85K
  • Bsn Medical Inc$72
  • GSK$15

What the payments were for

  • Consulting fees$3,3904%
  • Speaking & faculty fees$74,62088%
  • Travel & lodging$4,7976%
  • Food & beverage$1,8872%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead103$84,607
Bsn Medical Inc1$72
GSK1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,695 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$45,748
Medicare patients
111
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$75,933
VemlidyTenofovir Alafenamide26$40,138
FarxigaDapagliflozin Propanediol32$33,621
EliquisApixaban19$23,789
MounjaroTirzepatide13$16,751
Rosuvastatin Calcium286$5,599
Atorvastatin Calcium273$2,835
Amlodipine Besylate259$1,798
Losartan Potassium156$1,760
Albuterol Sulfate HfaAlbuterol Sulfate49$1,741
Levothyroxine Sodium131$1,439
Metformin Hcl202$1,402
Metoprolol Succinate77$1,397
Tamsulosin Hcl63$1,164
Lisinopril154$872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$84,607$40,13826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →